{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:58Z","timestamp":1760189278109},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T00:00:00Z","timestamp":1348704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00277-012-1579-y","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T02:04:57Z","timestamp":1348711497000},"page":"249-254","source":"Crossref","is-referenced-by-count":5,"title":["Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"92","author":[{"given":"Marta","family":"Krejci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvona","family":"Brychtova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Stehlikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Chovancova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana Skuhrova","family":"Francova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Navratil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Tomiska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Horky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,27]]},"reference":[{"key":"1579_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2009.141","volume":"45","author":"P Ljungman","year":"2010","unstructured":"Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al (2010) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 45:219\u2013234","journal-title":"Bone Marrow Transplant"},{"key":"1579_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","volume":"21","author":"P Dreger","year":"2007","unstructured":"Dreger P, Corradini P, Kimby E, Michallet M, Miligan D, Schetelig J et al (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12\u201317","journal-title":"Leukemia"},{"key":"1579_CR3","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German Study Group CLL3X trial. Blood 116:2438\u20132447","journal-title":"Blood"},{"key":"1579_CR4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2011.01639.x","volume":"87","author":"M Doubek","year":"2011","unstructured":"Doubek M, Mayer J, Obrtlikova P, Smolej L, Cmunt E, Schvarz J et al (2011) Modern and conventional prognostic markers of chronic lymphocytix leukaemia in the everyday haematological practice. Eur J Haematol 87:130\u2013137","journal-title":"Eur J Haematol"},{"key":"1579_CR5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.949","volume":"29","author":"V Valkova","year":"2011","unstructured":"Valkova V, Schwarz J, Vitek A, Markova M, Polhreich D, Benesova K et al (2011) The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis. Hematol Oncol 29:22\u201330","journal-title":"Hematol Oncol"},{"key":"1579_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2007.06591.x","volume":"137","author":"IF Khouri","year":"2007","unstructured":"Khouri IF, Saliba RM, Admirand J et al (2007) Graft-versus-leukaemia effect after non-myeloablative haematopoetic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137:355\u2013363","journal-title":"Br J Haematol"},{"key":"1579_CR7","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","volume":"26","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Sandmaier BM et al (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912\u20134920","journal-title":"J Clin Oncol"},{"key":"1579_CR8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","volume":"12","author":"JR Brown","year":"2006","unstructured":"Brown JR, Kim HT, Li S et al (2006) Predictors of improved progression-free survival after nonmyeloablativne allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056\u20131064","journal-title":"Biol Blood Marrow Transplant"},{"key":"1579_CR9","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G et al (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675\u20135687","journal-title":"J Clin Oncol"},{"issue":"S2","key":"1579_CR10","first-page":"411","volume":"93","author":"M Krejci","year":"2011","unstructured":"Krejci M, Brychtova Y, Doubek M, Toskova M, Racil Z, Koristek Z et al (2011) Efficacy and toxicity of the FLAMSA\/RIC regimen in 40 patients with high-risk AML: a single centre experience. Haematologica 93(S2):411\u2013412 (abstract 0987)","journal-title":"Haematologica"},{"key":"1579_CR11","first-page":"897","volume":"52","author":"V Gandhi","year":"1992","unstructured":"Gandhi V, Kemera A, Keating MJ, Plunket W (1992) Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897\u2013903","journal-title":"Cancer Res"},{"key":"1579_CR12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","volume":"26","author":"AM Tsimberidou","year":"2008","unstructured":"Tsimberidou AM, Wierda WG, Plunkett W et al (2008) Phase I\u2013II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patiens with Richter\u2019s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26:196\u2013203","journal-title":"J Clin Oncol"},{"key":"1579_CR13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdi238","volume":"16","author":"WH Kr\u00fcger","year":"2005","unstructured":"Kr\u00fcger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G et al (2005) Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Disease Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 16:1381\u20131390","journal-title":"Ann Oncol"},{"key":"1579_CR14","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825\u2013828","journal-title":"Bone Marrow Transplant"},{"key":"1579_CR15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"60","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL et al (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopatologic study of 20 Seattle patients. Am J Med 60:204\u2013217","journal-title":"Am J Med"},{"key":"1579_CR16","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) Gudelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"1579_CR17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/leu.2008.96","volume":"22","author":"M Ritgen","year":"2008","unstructured":"Ritgen M, B\u00f6ttcher S, Stilgenbauer S et al (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22:1377\u20131386","journal-title":"Leukemia"},{"key":"1579_CR18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.leu.2402760","volume":"17","author":"T Lion","year":"2003","unstructured":"Lion T (2003) Summary: reports on quantitative analysis of chimerim after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia 17:232\u2013254","journal-title":"Leukemia"},{"key":"1579_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1751-553X.2010.01249.x","volume":"33","author":"O Horky","year":"2011","unstructured":"Horky O, Mayer J, Kablaskova L, Razga F, Krejci M, Kissova J et al (2011) Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse. Int J Hematol 33:57\u201366","journal-title":"Int J Hematol"},{"key":"1579_CR20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956\u2013964","journal-title":"Leukemia"},{"key":"1579_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bmt.2009.105","volume":"44","author":"F Zohren","year":"2009","unstructured":"Zohren F, Czibere A, Bruns I et al (2009) Fludarabine, amsacrine, high-dose cytarabine and 12\u00a0Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant 44:1\u20138","journal-title":"Bone Marrow Transplant"},{"key":"1579_CR22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","volume":"107","author":"J Delgado","year":"2006","unstructured":"Delgado J, Thomson K, Russel N et al (2006) Results of alemtuzumab-based reduced intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood 107:1724\u20131730","journal-title":"Blood"},{"key":"1579_CR23","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2009-05-206821","volume":"114","author":"J Delgado","year":"2009","unstructured":"Delgado J, Miligan DW, Dreger P (2009) Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for primetime? Blood 114:2581\u20132588","journal-title":"Blood"},{"key":"1579_CR24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmidt","year":"2006","unstructured":"Schmidt C, Schleuning M, Schwerdtfeger R et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108:1092\u20131099","journal-title":"Blood"},{"key":"1579_CR25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.critrevonc.2004.05.008","volume":"51","author":"GL Banna","year":"2004","unstructured":"Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C et al (2004) Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 51:171\u2013189","journal-title":"Crit Rev Oncol Hematol"},{"key":"1579_CR26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol 10:855\u2013864","journal-title":"Lancet Oncol"},{"key":"1579_CR27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","volume":"19","author":"P Dreger","year":"2005","unstructured":"Dreger P, Brand R, Milligan D et al (2005) Reduced-intensity conditioning lowers treatment-relapted mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19:1029\u20131033","journal-title":"Leukemia"},{"key":"1579_CR28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3324\/haematol.2008.000273","volume":"94","author":"L Farina","year":"2009","unstructured":"Farina L, Carniti C, Doredo A et al (2009) Qualitative and quantitative polymerase chain reaction monitoring of minimal residual duseiase in relaposed chronic lymphocytic leukemia: early assesment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 94:654\u2013662","journal-title":"Haematologica"},{"key":"1579_CR29","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2005-09-3634","volume":"107","author":"C Moreno","year":"2006","unstructured":"Moreno C, Villamor N, Esteve J et al (2006) Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107:1563\u20134569","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1579-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1579-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1579-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T07:19:58Z","timestamp":1562224798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1579-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1579"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1579-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,27]]}}}